Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Inclusion Criteria: * Male and female subjects with mild to moderate AD (IGA 2 or 3) 18 to 65 years of age,inclusive. The health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease other than AD following a detailed medical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, virology and urinalysis; * Confirmed AD diagnosis; * Symptoms present for at least 1 year; * EASI between 7.1 - 50.0, inclusive at screening; * 2-20% body surface area (BSA) affected at screening; * Body mass index (BMI) between 18 and 35 kg/m2, inclusive, and with a minimum weight of 50 kg; * Able to participate and willing to give written informed consent and to comply with the study restrictions; * Subjects and their partners of childbearing potential must use effective contraception, for the duration of the study and for 3 months after the last dose. Exclusion Criteria: * Any current and / or recurrent clinical significant skin condition other than AD; * Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding; * Ongoing use of prohibited atopic dermatitis treatments. Requires washout period prior to baseline (first dose of the study drug); * Use of topical medication (prescription or over-the-counter \[OTC\]) within 14 days of study drug administration, or less than 5 half-lives (whichever is longer) in local treatment area; * Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of enrollment; * Known hypersensitivity to the compound or excipients of the compound or known hypersensitivity to one or more different emollients; * Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year; * Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.